Sagimet Biosciences Inc
SGMT8.450USD
+0.200+2.42%
收盘 08/04, 16:00（美东）报价延迟15分钟
272.05M总市值
亏损市盈率 TTM
关于 Sagimet Biosciences Inc 公司
Sagimet Biosciences Inc. 是一家临床阶段的生物制药公司。该公司致力于开发一种称为脂肪酸合酶 (FASN) 抑制剂的治疗药物，该药物针对因脂肪酸棕榈酸酯过量生产而导致的疾病中功能失调的代谢途径。该公司的主要候选药物 denifanstat 是一种口服、每日一次的药丸，也是正在开发的用于治疗代谢功能障碍相关脂肪性肝炎 (MASH) 的选择性 FASN 抑制剂。除了 MASH，该公司还在评估 denifanstat 在痤疮和特定形式的癌症中的作用，在这些疾病领域中，脂肪酸代谢失调也起着关键作用。Denifanstat 正在进行中度至重度寻常痤疮的 III 期临床试验，以及与贝伐单抗联合治疗复发性多形性胶质母细胞瘤 (GBM) 的 III 期试验。
公司简介
公司代码SGMT
公司名称Sagimet Biosciences Inc
上市日期Jul 14, 2023
CEOMr. David Happel
员工数量14
证券类型Ordinary Share
年结日Jul 14
公司地址155 Bovet Rd., Suite 303
城市SAN MATEO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94402
电话16505618600
网址https://sagimet.com/
公司代码SGMT
上市日期Jul 14, 2023
CEOMr. David Happel
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
183.73K
-5.54%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
Mr. Paul W. Hoelscher
Mr. Paul W. Hoelscher
Independent Director
Independent Director
--
--
Mr. Thierry Chauche
Mr. Thierry Chauche
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Elizabeth Grammer, Esq.
Ms. Elizabeth Grammer, Esq.
Independent Director
Independent Director
--
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
183.73K
-5.54%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
KPCB PBD Associates LLC
6.19%
Point72 Asset Management, L.P.
5.72%
AP11 Limited
4.91%
Blue Owl Capital Holdings LP
4.33%
Alyeska Investment Group, L.P.
3.89%
Other
74.96%
持股股东
持股股东
占比
KPCB PBD Associates LLC
6.19%
Point72 Asset Management, L.P.
5.72%
AP11 Limited
4.91%
Blue Owl Capital Holdings LP
4.33%
Alyeska Investment Group, L.P.
3.89%
Other
74.96%
股东类型
持股股东
占比
Hedge Fund
19.57%
Investment Advisor
14.64%
Corporation
11.58%
Investment Advisor/Hedge Fund
7.50%
Research Firm
2.27%
Individual Investor
1.46%
Pension Fund
0.60%
Bank and Trust
0.10%
Private Equity
0.04%
Other
42.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
201
18.06M
58.88%
-8.71M
2025Q1
199
18.50M
63.07%
-6.39M
2024Q4
183
22.20M
72.39%
-4.47M
2024Q3
166
24.34M
79.36%
-2.24M
2024Q2
157
25.83M
85.10%
-301.40K
2024Q1
134
27.23M
89.77%
+13.80M
2023Q4
94
18.02M
81.13%
+2.10M
2023Q3
73
15.74M
73.17%
+13.03M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
KPCB PBD Associates LLC
1.90M
6.19%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.76M
5.72%
-561.43K
-24.24%
Mar 31, 2025
AP11 Limited
1.50M
4.91%
-150.06K
-9.07%
Jun 24, 2025
Blue Owl Capital Holdings LP
1.33M
4.33%
+4.47K
+0.34%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.19M
3.89%
-98.07K
-7.60%
Mar 31, 2025
The Vanguard Group, Inc.
1.15M
3.76%
+22.73K
+2.01%
Mar 31, 2025
Baker Bros. Advisors LP
953.00K
3.11%
--
--
Mar 31, 2025
Rock Springs Capital Management LP
787.81K
2.57%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
724.80K
2.36%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
724.77K
2.36%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.02%
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Growth ETF
占比0%
iShares Health Innovation Active ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Global X Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
